FY2024 Earnings Estimate for ALUR Issued By Chardan Capital

Allurion Technologies Inc. (NYSE:ALUR) – Stock analysts at Chardan Capital lifted their FY2024 earnings per share estimates for Allurion Technologies in a research report issued on Sunday, January 12th. Chardan Capital analyst K. Nakae now anticipates that the company will post earnings per share of ($7.63) for the year, up from their previous estimate of ($7.75). Chardan Capital has a “Neutral” rating on the stock. The consensus estimate for Allurion Technologies’ current full-year earnings is ($0.41) per share. Chardan Capital also issued estimates for Allurion Technologies’ FY2025 earnings at ($4.82) EPS.

Separately, TD Cowen initiated coverage on Allurion Technologies in a research report on Wednesday, October 2nd. They issued a “buy” rating and a $50.00 price target for the company. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $71.88.

Allurion Technologies Trading Up 13.8 %

ALUR opened at $3.57 on Wednesday. The firm has a market cap of $230.06 million, a P/E ratio of -7.45 and a beta of -0.56. Allurion Technologies has a 12 month low of $2.72 and a 12 month high of $98.75. The stock has a 50-day moving average of $9.66 and a 200 day moving average of $15.79.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Allurion Technologies stock. CVI Holdings LLC purchased a new stake in Allurion Technologies Inc. (NYSE:ALUR) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 521,440 shares of the company’s stock, valued at approximately $520,000. Allurion Technologies accounts for 0.5% of CVI Holdings LLC’s investment portfolio, making the stock its 28th largest position. CVI Holdings LLC owned 1.09% of Allurion Technologies at the end of the most recent quarter. Hedge funds and other institutional investors own 21.39% of the company’s stock.

Allurion Technologies Company Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.